Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

著者: Sandra M. Swain, Sung‐Bae Kim, Javier Cortés, Jungsil Ro, Semiglazov Vf, Mario Campone, Eva Ciruelos, Jean-­Marc Ferrero, Andreas Schneeweiß, Adam Knott, Emma Clark, Graham Ross, Mark Benyunes, José Baselga - The Lancet 2013 被引用: 1,000